Icon

KEPPRA XR (nda022285)- (500MG,750MG)

LEVETIRACETAM UCB INC
500MG,750MG
Yes No
2029-Mar-17 Expired
None None
None No
KEPPRA XR is indicated for the treatment of partial-onset seizures in patients 12 years of age and older.
13 0 8
Total Other Developers 11
Drugs with Suitability Yes
500MG ** ** Up 6 -
750MG ** ** Up 6 -
NDA Sales Available Total Generic Sales Available
Yes 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** *** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ***** *** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** *****-****** *******, *****, ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** **** ********** ******************** ****. *********** ** ********* ****, *******, ******* *** ***, ****** (***) ***
****** **** ********** ******** ****** ******* ******* *** *********** ****-**, **.**'*.**,**,**,**,** ** **,***&***, ************** * & **.** *,*,****,**,**,**,**&**, ************ *, *********** ******, **********, ****** ******* ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ******** ******* ************ ******* *** *********** **** *, **. **: ***, ***, ***, ***/*, **************** ****** ****, *********** *******, *********** ******,, **********, ********* ***** ******, ***** (***) ***
****** ******** ******** ******** ************** **., *** *********** **, ****** ****, ****** ****, ******* ********, ******, ******** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.